Clinical Trials Logo

Metaplasia clinical trials

View clinical trials related to Metaplasia.

Filter by:

NCT ID: NCT01614418 Completed - Clinical trials for Intestinal Metaplasia

Radiofrequency Ablation for Gastric Metaplasia and Dysplasia

Start date: September 2011
Phase: Phase 1/Phase 2
Study type: Interventional

Gastric intestinal metaplasia (IM) and dysplasia, also referred to as intra-epithelial neoplasia, are well recognized precursors of gastric cancer. Apart from endoscopic surveillance, there is no other intervention which predictably eradicates pre-cancerous gastric lesions. Endoscopic radiofrequency ablative (RFA) therapy has been recently shown to be highly effective in eradicating both IM and dysplasia in patients with Barrett's esophagus. However, the potential role of RFA to remove gastric IM and dysplasia remains unknown. In this study, we determine the feasibility of using endoscopic RFA in treating early gastric neoplasia (metaplasia and dysplasia). Patients with gastric metaplasia and/or dysplasia will be treated with endoscopic RFA. The safety and effects of RFA will be determined.

NCT ID: NCT01499576 Completed - Stomach Neoplasms Clinical Trials

Acetic Acid Chromoendoscopy to Judge Gastric Intestinal Metaplasia

IM
Start date: November 2011
Phase: N/A
Study type: Interventional

The presence and the extent of gastric intestinal metaplasia(IM) is a good indicator of high risk group of gastric cancer. Many methods was developed to survey it, including multiple gastric biopsy or methylene blue chromoendoscopy. But they are not practical in the routine screening exam, limited by cost and accessibility. Spraying of acetic acid is commonly used in screening cervical cancer, to induce whitish discoloration of metaplastic mucosa. The investigators have confirmed such whitish discoloration is induced in gastric IM, with accuracy > 80% in a pilot study of the investigators. This prospective study will tell the accuracy, sensitivity and specificity of acetic acid chromoendoscopy for judging gastric IM.

NCT ID: NCT01491724 Unknown status - Clinical trials for Gastric Intestinal Metaplasia

The Learning Curve of Probe-based Confocal Laser Endomicroscopy (pCLE) Images Interpretation in Gastric Intestinal Metaplasia (GIM)

Start date: September 2011
Phase: N/A
Study type: Observational

The Learning Curve of Probe-based Confocal Laser Endomicroscopy (pCLE) images interpretation in Gastric Intestinal Metaplasia (GIM) Objective: The aim of this study is to evaluate the learning curve of pCLE images interpretation in GIM. Research design: Blinded review of pCLE images for the diagnosis of GIM Sample size: Five beginner endoscopists will be assigned in this study to read approximately 80 videoclips Data analysis: ROC curve is analyzed by SPSS version 16. Expected Benefit and Clinical Application Information on the learning curve for GIM interpretation from pCLE images in order to develop early gastric cancer detection

NCT ID: NCT01490541 Recruiting - Clinical trials for Gastric Intestinal Metaplasia

The Predictive Scores for Gastric Cancer in Gastric Intestinal Metaplasia (GIM) Patient: a Recommendation for Thai Population

Start date: October 2011
Phase: N/A
Study type: Observational

The predictive scores for gastric cancer in gastric intestinal metaplasia(GIM) patient: a recommendation for Thai population. Objective: To evaluate major risk factors for gastric cancer in gastric intestinal metaplasia(GIM) patient in order to propose the appropriate recommendation for Thai people. Research Design: Single center, retrospective-cohort study.

NCT ID: NCT01489397 Completed - Clinical trials for Gastric Intestinal Metaplasia

Magnified Intelligence Chromoendoscopy Plus Probe-based Confocal Laser Endomicroscopy for Gastric Intestinal Metaplasia Diagnosis

Start date: April 2010
Phase: N/A
Study type: Interventional

Magnified intelligence chromoendoscopy (FICE) plus probe-based confocal laser endomicroscopy (pCLE) for Gastric Intestinal Metaplasia (GIM) diagnosis: a feasibility trial Research Question: Is confocal endomicroscope feasible to diagnose gastric intestinal metaplasia? Objective: To evaluate the feasibility of confocal endomicroscope in diagnose gastric intestinal metaplasia. Hypothesis: Confocal endomicreosocpe can provide the accurate diagnosis of gastric intestinal metaplasia. Research design: Diagnostic study Sample size: The investigators follow the population in recent study from Imraporn et al.: Validity of magnify NBI for gastric intestinal metaplasia targeted biopsy (N= 50) Data analysis: Confocal Barrett's esophagus classification was used to evaluate agreement of confocal endomicroscopic finding in gastric intestinal metaplasia. The accuracy of new criteria for GIM by confocal endomicroscope was evaluated in relation to pathological report, a gold standard for diagnosis, and reported as sensitivity, specificity, positive predictive value, negative predictive value and accuracy of these criteria. Expected Benefit and Application: The feasibility of confocal endomicroscopy for diagnosis gastric intestinal metaplasia in order to improve the quality of GIM/dysplasia/early gastric cancer detection and then decrease the mortality rate from gastric cancer in the future.

NCT ID: NCT01398579 Recruiting - Clinical trials for Intestinal Metaplasia

Comparison Between Probe-based Confocal Laser Endomicroscopy, White-light Endoscopy and Virtual Chromoendoscopy

pCLE-GCEP
Start date: September 2011
Phase: Phase 1
Study type: Interventional

The investigators hypothesis that 1. clinical applicability and overall diagnostic sensitivity and specificity of pCLE for diagnosing gastric preneoplastic and neoplastic lesions is acceptable 2. pCLE, as compared to white-light endoscopy (WLE), AFI and magnifying NBI has higher sensitivity and specificity for the diagnosing gastric pre-neoplastic and neoplastic lesions

NCT ID: NCT01384201 Completed - Clinical trials for Gastric Intestinal Metaplasia

Confocal Endomicroscopy Detection of Gastric Preneoplasia and Neoplasia

R-CE-GCEP
Start date: August 2007
Phase: N/A
Study type: Observational

This is a prospective randomised study investigating the use of chromoendoscopy and confocal laser endomicroscopy for the detection of preneoplastic neoplasm in patients at high-risk of gastric cancer.

NCT ID: NCT01374074 Completed - Barrett's Esophagus Clinical Trials

Racial Disparity in Barrett's Esophagus

Start date: March 2011
Phase: N/A
Study type: Observational

The goal of the proposed research is to investigate the molecular mechanisms of racial disparity in Barrett's esophagus (BE), the premalignant lesion of esophageal adenocarcinoma. Specifically, the investigators hypothesize that environmental factors, genetic factors, and potentially gene environment interactions play crucial roles in the observed racial disparity in developing Barrett's esophagus. Patients are recruited through UNC hospitals prior to scheduled esophagogastroduodenoscopy (EGD). Participants complete a questionnaire, have body measurements obtained, and have blood, biopsies, and gastric aspirate collected. Participants also complete a 24 hour pH impedance test.

NCT ID: NCT01373125 Completed - Barrett's Esophagus Clinical Trials

Is the Neosquamous Epithelium "Normal" Following Endoscopic Ablation of Dysplastic Barrett's Esophagus?

Start date: June 2011
Phase: N/A
Study type: Observational

The investigators propose a study comparing the morphological and functional aspects of the neosquamous epithelium (NSE) after ablative therapy for dysplastic Barrett's esophagus (BE) to that of native squamous epithelium in normal controls as well as gastroesophageal reflux disease (GERD), non-Barrett's Esophagus (BE) subjects.

NCT ID: NCT01093222 Completed - Clinical trials for Hilar Cholangiocarcinoma

Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma

Start date: April 2010
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well giving sorafenib tosylate together with erlotinib hydrochloride works in treating patients with locally advanced, unresectable, or metastatic gallbladder cancer or cholangiocarcinoma. Sorafenib tosylate and erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the tumor.